Fabio Chianelli - Pharmather Holdings Chairman CEO
| PHRRF Stock | USD 0.16 0.01 5.88% |
Insider
Fabio Chianelli is Chairman CEO of Pharmather Holdings
| Age | 45 |
| Phone | 888 846 3171 |
| Web | https://www.pharmather.com |
Pharmather Holdings Management Efficiency
The company has return on total asset (ROA) of (0.2465) % which means that it has lost $0.2465 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6321) %, meaning that it generated substantial loss on money invested by shareholders. Pharmather Holdings' management efficiency ratios could be used to measure how well Pharmather Holdings manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| DDS MS | Aditxt Inc | 59 | |
| Thomas CPA | Aditxt Inc | 51 | |
| MS MBA | XOMA Corporation | 67 | |
| Bradley JD | Lumos Pharma | 45 | |
| Florian M | GH Research PLC | 55 | |
| Amro Albanna | Aditxt Inc | 54 | |
| Carl Langren | Lumos Pharma | 69 | |
| Richard Hawkins | Lumos Pharma | 75 | |
| CPA CPA | Aditxt Inc | 56 | |
| III CFA | Checkpoint Therapeutics | 46 | |
| Catherine Fratila | Adial Pharmaceuticals | N/A | |
| Matthew Shatzkes | Aditxt Inc | N/A | |
| Rowena Albanna | Aditxt Inc | 58 | |
| Alex Lugovoy | Adial Pharmaceuticals | N/A | |
| Julie ACA | GH Research PLC | 38 | |
| Thomas Schaible | Fortress Biotech | N/A | |
| Mark Peikin | Adial Pharmaceuticals | N/A | |
| Thomas Burns | XOMA Corporation | 49 | |
| Robert Dudley | Transcode Therapeutics | 73 | |
| Lisa Miller | Lumos Pharma | N/A | |
| Anna Moore | Transcode Therapeutics | 62 | |
Management Performance
| Return On Equity | -0.63 | |||
| Return On Asset | -0.25 |
Pharmather Holdings Management Team
Elected by the shareholders, the Pharmather Holdings' board of directors comprises two types of representatives: Pharmather Holdings inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pharmather. The board's role is to monitor Pharmather Holdings' management team and ensure that shareholders' interests are well served. Pharmather Holdings' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pharmather Holdings' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Fabio Chianelli, Chairman CEO | ||
| Andrew Todd, Co Sec | ||
| ACIS BComm, Chief Officer |
Pharmather Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Pharmather Holdings a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.63 | |||
| Return On Asset | -0.25 | |||
| Current Valuation | (3.24 M) | |||
| Shares Outstanding | 88.17 M | |||
| Shares Owned By Insiders | 18.67 % | |||
| Shares Owned By Institutions | 0.06 % | |||
| Price To Earning | 2.26 X | |||
| Price To Book | 0.57 X | |||
| EBITDA | (4.1 M) | |||
| Net Income | (4.01 M) |
Currently Active Assets on Macroaxis
Other Information on Investing in Pharmather OTC Stock
Pharmather Holdings financial ratios help investors to determine whether Pharmather OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pharmather with respect to the benefits of owning Pharmather Holdings security.